Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-EPCAM, 17-1A Vector   (CAT#: GTVCR-WQ52MR)

This product GTVCR-WQ52MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting EPCAM. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Mus musculus
RefSeq NM_002354.3
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 4072
UniProt ID P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-EPCAM, 17-1A Vector (GTVCR-WQ52MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ1808MR IVTScrip™ pT7-VEE-mRNA-Anti-G, M777-16-3 Vector Vector M777-16-3
GTVCR-WQ1148MR IVTScrip™ pT7-VEE-mRNA-Anti-IL3RA, DT-IL-3 Vector Vector DT-IL-3
GTVCR-WQ1027MR IVTScrip™ pT7-VEE-mRNA-Anti-IL6, COR-001 Vector Vector COR-001
GTVCR-WQ1428MR IVTScrip™ pT7-VEE-mRNA-Anti-B4GALNT1, Hu3F8 Vector Vector Hu3F8
GTVCR-WQ860MR IVTScrip™ pT7-VEE-mRNA-Anti-CD52, Campath-1H Vector Vector Campath-1H
GTVCR-WQ610MR IVTScrip™ pSP6-VEE-mRNA-Anti-LYPD3, BAY 1129980 Vector Vector BAY 1129980
GTVCR-WQ268MR IVTScrip™ pT7-VEE-mRNA-Anti-BMP10&GDF2, ACE-041 Vector Vector ACE-041
GTVCR-WQ939MR IVTScrip™ pT7-VEE-mRNA-Anti-IL13, CDP7766 Vector Vector CDP7766
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW